Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus
Journal Title: National Journal of Physiology, Pharmacy and Pharmacology - Year 2018, Vol 8, Issue 4
Abstract
Background: Diabetes mellitus is a heterogeneous chronic metabolic disorder principally characterized by persistent hyperglycemia resulting from defects in insulin action and/or insulin secretion. In course of time, prolonged hyperglycemia and associated metabolic aberrations result in tissue toxicity manifested as accelerated atherosclerosis, renoretinal microangiopathy, and neuropathy leading to a variety of vascular, neurological, and focal complications. Aim and Objective: The aim of this study is to evaluate the efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients with Type 2 diabetes mellitus. Materials and Methods: This is a longitudinal interventional study. A total of 60 patients were enrolled in the study. Those patients who were already on metformin 500 mg bid with poor glycemic control were included in the study. These 60 patients were divided into two groups each consisting of 30 patients. Group A patients received glimepiride 1 mg bid and metformin 500 mg bid. Group B patients received vildagliptin 50 mg bid and metformin 500 mg bid. The total period of the study was 3 months. Results: After 3 months of treatment, both the groups caused a significant decline in blood glucose levels both fasting blood sugar (FBS) as well as postprandial blood sugar (PPBS) levels. There was a significant difference between the two groups in reducing the FBS levels and PPBS. Hemoglobin A1c (HbA1c) was also reduced significantly in both groups at 12 weeks. After 3 months of therapy, there was a reduction in HbA1C in B group. The reduction of HbA1C was not statistically significant between the two groups. Adverse effects were more with metformin and glimepiride group at the end of 3 months therapy. There was a significant difference in the incidence of adverse effects between both the groups. Conclusions: Vildagliptin and metformin combination provided better efficacy comparable to that of glimepiride and metformin combination and resulted in better adverse effect profile with lower risks of hypoglycemia and weight gain.
Authors and Affiliations
Harinika Gullapalli, Savithri Desai
Keywords
Related Articles
- EP ID EP487759
- DOI 10.5455/njppp.2018.8.1143618112017
- Views 32
- Downloads 0
Influence of menopause on cardiovascular responses to behavioral stressors: A comparative study
Background: There is increased cardiovascular morbidity and mortality in post-menopausal women as compared to pre-menopausal women. There is an altered autonomic control with a shift toward sympathetic hyperactivity in m...
Investigation of phytochemical constituents in Azolla microphylla for antibacterial activity
Background: Modern day food and lifestyle have resulted in an increasing number of diseases and disorders. A major percentage of the population depends on herbal medicines due to various needs. Aim and objective: The aim...
Biochemical assessment of the hepatic functions of the petrol pump workers of Jaipur city
Background: In recent years, occupational health hazards have grown as one of the major public health issues worldwide. In this context, petrol pump workers were studied who by virtue of their occupation is continuously...
Anticonvulsive effects of nifedipine and flunarizine on maximal electroshock seizures induced seizures
Background: Epilepsy is a common neurological disorder but the mechanism of seizure generation has been only partially unraveled. Currently available antiepileptics have a low therapeutic index and furthermore, provide s...
Study of auditory and visual reaction time across various phases of menstrual cycle
Background: The reproductive system of women shows regular cyclic changes that teleologically may be regarded as periodic preparations for fertilization and pregnancy. These cyclical changes are also associated with cycl...